Kwality Pharmaceuticals Past Earnings Performance
Past criteria checks 1/6
Kwality Pharmaceuticals has been growing earnings at an average annual rate of 23.6%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 14% per year. Kwality Pharmaceuticals's return on equity is 5.6%, and it has net margins of 4.2%.
Key information
23.6%
Earnings growth rate
23.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 14.0% |
| Return on equity | 5.6% |
| Net Margin | 4.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Kwality Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2,840 | 120 | 316 | 0 |
| 30 Sep 23 | 2,621 | 115 | 317 | 0 |
| 30 Jun 23 | 2,483 | 143 | 316 | 0 |
| 31 Mar 23 | 2,510 | 194 | 301 | 0 |
| 31 Dec 22 | 2,480 | 369 | 281 | 0 |
| 30 Sep 22 | 2,799 | 456 | 262 | 0 |
| 30 Jun 22 | 4,062 | 962 | 222 | 0 |
| 31 Mar 22 | 4,562 | 1,200 | 203 | 0 |
| 31 Dec 21 | 4,634 | 1,139 | 191 | 0 |
| 30 Sep 21 | 4,473 | 1,022 | 179 | 0 |
| 30 Jun 21 | 3,232 | 460 | 167 | 0 |
| 31 Mar 21 | 2,631 | 151 | 160 | 0 |
| 31 Dec 20 | 2,266 | 131 | 146 | 0 |
| 30 Sep 20 | 1,897 | 110 | 162 | 0 |
| 30 Jun 20 | 1,661 | 97 | 158 | 0 |
| 31 Mar 20 | 1,425 | 83 | 124 | 0 |
| 31 Dec 19 | 1,550 | 83 | 119 | 0 |
| 30 Sep 19 | 1,675 | 82 | 111 | 0 |
| 30 Jun 19 | 1,671 | 79 | 99 | 0 |
| 31 Mar 19 | 1,667 | 76 | 90 | 0 |
| 31 Dec 18 | 1,578 | 64 | 77 | 0 |
| 30 Sep 18 | 1,488 | 53 | 64 | 0 |
| 30 Jun 18 | 1,434 | 49 | 61 | 0 |
| 31 Mar 18 | 1,380 | 45 | 57 | 0 |
| 31 Dec 17 | 1,266 | 47 | 54 | 0 |
| 30 Sep 17 | 1,144 | 49 | 50 | 0 |
| 30 Jun 17 | 1,069 | 41 | 47 | 0 |
| 31 Mar 17 | 993 | 34 | 44 | 0 |
| 31 Dec 16 | 933 | 28 | 40 | 0 |
| 30 Sep 16 | 840 | 22 | 35 | 0 |
| 30 Jun 16 | 792 | 19 | 31 | 0 |
| 31 Mar 16 | 744 | 16 | 28 | 0 |
| 31 Mar 15 | 526 | 8 | 21 | 0 |
| 31 Mar 14 | 597 | 9 | 18 | 0 |
Quality Earnings: 539997 has a large one-off loss of ₹164.8M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 539997's current net profit margins (4.2%) are lower than last year (14.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 539997's earnings have grown significantly by 23.6% per year over the past 5 years.
Accelerating Growth: 539997's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 539997 had negative earnings growth (-67.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.1%).
Return on Equity
High ROE: 539997's Return on Equity (5.6%) is considered low.